Tevogen Bio Holdings Inc. (TVGN) 10-Year Financial Performance & Capital Metrics

TVGN • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutTevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.Show more

Revenue $0
EBITDA -$53M -528.0%
Net Income -$10M +83.3%
EPS (Diluted) -0.09 -23300.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -291.05 -742.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 11.3% through buybacks

✗Weaknesses

✗Weak momentum: RS Rating 4 (bottom 4%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-612.87%

EPS CAGR

10Y-

5Y-

3Y-

TTM47.61%

ROCE

10Y Avg-892.72%

5Y Avg-892.72%

3Y Avg-1306.05%

Latest-

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	378.36K	403.58K
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	-378.36K	-403.58K
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-0.07%
Operating Expenses+	4.62M	953.08K	8.46M	53.16M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	1.66M	953.08K	4.06M	22.13M
SG&A % of Revenue	-	-	-	-
Research & Development	2.96M	0	4.4M	31.03M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	0	0
Operating Income+	-4.62M	-953.08K	-8.84M	-53.56M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	0.79%	-8.28%	-5.06%
EBITDA+	-4.61M	4.41M	-8.46M	-53.16M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	1.96%	-2.92%	-5.28%
D&A (Non-Cash Add-back)	9.38K	0	378.36K	403.58K
EBIT	-15M	4.41M	-59.27M	-13.54M
Net Interest Income+	-598.5K	0	-256.03K	-184.04K
Interest Income	0	0	0	0
Interest Expense	598.5K	0	256.03K	184.04K
Other Income/Expense	-10.98M	5.36M	-51.63M	39.84M
Pretax Income+	-15.6M	4.41M	-60.48M	-13.73M
Pretax Margin %	-	-	-	-
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.74%
Net Income+	-15.6M	4.41M	-60.48M	-10.11M
Net Margin %	-	-	-	-
Net Income Growth %	-	1.28%	-14.72%	0.83%
Net Income (Continuing)	-15.6M	4.41M	-60.48M	-13.73M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.33	0.04	-0.00	-0.09
EPS Growth %	-	1.11%	-1.01%	-
EPS (Basic)	-0.33	0.04	-0.00	-0.09
Diluted Shares Outstanding	47.93M	120M	165.42M	146.67M
Basic Shares Outstanding	47.93M	120M	165.42M	146.67M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.17M	5.84M	1.72M	2.36M
Cash & Short-Term Investments	7.12M	5.48M	1.05M	1.28M
Cash Only	7.12M	5.48M	1.05M	1.28M
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	158.82K
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	53.96K	0	0	919.09K
Total Non-Current Assets+	485.27K	1.9M	3.78M	1.1M
Property, Plant & Equipment	142.62K	1.31M	928.51K	524.93K
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	351.92M	0	0	0
Other Non-Current Assets	-351.57M	594.88K	2.85M	575.84K
Total Assets+	7.66M	7.74M	5.51M	3.46M
Asset Turnover	-	-	-	-
Asset Growth %	-	0.01%	-0.29%	-0.37%
Total Current Liabilities+	667.94K	1.96M	85.48M	9.04M
Accounts Payable	378K	865.91K	3.42M	5.2M
Days Payables Outstanding	-	-	3.3K	4.7K
Short-Term Debt	0	0	80.71M	1.65M
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	45.27K	237.6K	120.15K	403.23K
Current Ratio	10.74x	2.98x	0.02x	0.26x
Quick Ratio	10.74x	2.98x	0.02x	0.26x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	23.48M	39.73M	14.45M	1.09M
Long-Term Debt	23.48M	39.3M	14.22M	1M
Capital Lease Obligations	0	432.73K	234.86K	5.8K
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	87.18K
Total Liabilities	24.15M	41.69M	99.93M	10.14M
Total Debt+	23.48M	40.01M	95.42M	2.89M
Net Debt	16.36M	34.52M	94.37M	1.6M
Debt / Equity	-	-	-	-
Debt / EBITDA	-	9.08x	-	-
Net Debt / EBITDA	-	7.83x	-	-
Interest Coverage	-7.72x	-	-34.54x	-291.05x
Total Equity+	-16.49M	-33.95M	-94.43M	-6.67M
Equity Growth %	-	-1.06%	-1.78%	0.93%
Book Value per Share	-0.34	-0.28	-0.57	-0.05
Total Shareholders' Equity	-16.49M	-33.95M	-94.43M	-6.67M
Common Stock	63.88K	61.88K	12K	17.8K
Retained Earnings	-17.14M	-39.18M	-99.66M	-113.39M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.27M	-8.66M	-8.17M	-12M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	-0.64%	0.06%	-0.47%
Net Income	-15.6M	-22.04M	-60.48M	-13.73M
Depreciation & Amortization	9.38K	230.82K	378.36K	403.58K
Stock-Based Compensation	582.41K	4.58M	0	40.76M
Deferred Taxes	0	0	0	0
Other Non-Cash Items	10.98M	8.67M	51.63M	-39.43M
Working Capital Changes	-1.25M	-96.92K	293.2K	-5.49K
Change in Receivables	0	0	-267K	0
Change in Inventory	0	0	0	0
Change in Payables	-1.09M	0	1.11M	1.69M
Cash from Investing+	-109.73K	-479.04K	-133K	0
Capital Expenditures	-109.73K	-479.04K	-133K	0
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	0
Cash from Financing+	12.5M	7.5M	3.87M	12.23M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	0	342.86M	229.33K
Net Change in Cash	-	-	-	-
Free Cash Flow+	-5.38M	-9.13M	-8.3M	-12M
FCF Margin %	-	-	-	-
FCF Growth %	-	-0.7%	0.09%	-0.44%
FCF per Share	-0.11	-0.08	-0.05	-0.08
FCF Conversion (FCF/Net Income)	0.34x	-1.96x	0.14x	1.19x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Invested Capital (ROIC)	-	-322.18%	-2597.18%	-
Interest Coverage	-7.72x	-	-34.54x	-291.05x
FCF Conversion	0.34x	-1.96x	0.14x	1.19x

Frequently Asked Questions

Growth & Financials

Tevogen Bio Holdings Inc. (TVGN) grew revenue by 0.0% over the past year. Growth has been modest.

Tevogen Bio Holdings Inc. (TVGN) reported a net loss of $30.8M for fiscal year 2024.

Dividend & Returns

Tevogen Bio Holdings Inc. (TVGN) had negative free cash flow of $13.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener